Jacob Johnson
Stock Analyst at Stephens & Co.
(2.88)
# 1,546
Out of 5,161 analysts
78
Total ratings
45.76%
Success rate
8.57%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $212.35 | +13.02% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.01 | -0.17% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $6.61 | -9.23% | 5 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $21.37 | +180.77% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $186.26 | +69.12% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $475.89 | +42.89% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $113.76 | +49.44% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $2.67 | +87.27% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $0.84 | +1,217.37% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $14.64 | +159.56% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $7.72 | +120.21% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.70 | +47.06% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $51.47 | +69.03% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $231.09 | +68.77% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $7.98 | +125.56% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.71 | +250.88% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $18.15 | +59.78% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $211.48 | -38.53% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $152.66 | +146.95% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $212.35
Upside: +13.02%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.01
Upside: -0.17%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $6.61
Upside: -9.23%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $21.37
Upside: +180.77%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $186.26
Upside: +69.12%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $475.89
Upside: +42.89%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $113.76
Upside: +49.44%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $2.67
Upside: +87.27%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $0.84
Upside: +1,217.37%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $14.64
Upside: +159.56%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $7.72
Upside: +120.21%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.70
Upside: +47.06%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $51.47
Upside: +69.03%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $231.09
Upside: +68.77%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $7.98
Upside: +125.56%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $1.71
Upside: +250.88%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $18.15
Upside: +59.78%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $211.48
Upside: -38.53%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $152.66
Upside: +146.95%